Drug testing tells you what a worker used last week. It tells you nothing about what their brain is doing right now. ClearGazeTest measures 12 neurological biomarkers from eye movements in 5 minutes — detecting real-time functional impairment from cannabis, alcohol, fatigue, medications, and polydrug use. Before they clock in. Before they take off.
"Standard drug testing is backward-looking. It finds exposure, not impairment. Eye-based assessment measures what the brain is doing right now — before an operator touches a control surface, a wheel, or a throttle."
Traditional drug testing was designed for one purpose: detecting whether an employee used a prohibited substance at some point in the recent past. A urine test for cannabis can be positive for 30+ days after last use in a regular consumer. A hair follicle test can detect use from 90 days ago.
None of that tells you whether the pilot boarding the aircraft, the truck driver pulling onto the interstate, or the equipment operator mounting a 400-ton machine is functionally impaired right now. It tells you about last week. Last month. A drug test is a backward-looking compliance tool, not a real-time safety instrument.
As cannabis legalization spreads across North America, the backward-looking problem becomes acute. A commercial pilot in a legal cannabis state who uses cannabis on their day off may be entirely clean and unimpaired when they report for duty — or they may not be. A standard drug test cannot distinguish these. Only a real-time functional assessment can.
Fatigue and prescription medications compound the problem. An employee with a valid Ambien prescription who took it at 11pm may still be functionally impaired at 6am — and will pass every drug test your program has. The question that matters is always the same: is this person neurologically fit to operate this equipment, fly this aircraft, or drive this vehicle right now?
Detects metabolites present days to weeks after substance use. Does not measure intoxication, impairment, or current neurological function. A positive test means exposure happened — not that the person is impaired now. A negative test means nothing about current functional state.
Even less correlated with impairment — detects drug use from up to 90 days prior. An entirely accurate tool for long-term use pattern detection and compliance monitoring. Has no relationship whatsoever to current functional fitness.
Depends entirely on supervisor training, vigilance, and willingness to escalate — and is subject to bias, fatigue, and interpersonal dynamics. Alcohol impairment at moderate levels is frequently missed by untrained observers. Cannabis and prescription drug impairment is even harder to detect visually.
Eye movements reflect what the brain is actually doing right now. By measuring 12 oculomotor biomarkers in 5 minutes, ClearGazeTest determines whether the brain is functioning within normal parameters at the time of assessment — regardless of what was consumed, when, or at what dose. It catches impairment that drug tests miss and clears workers that drug tests would falsely flag.
In safety-sensitive roles, the gap between "passed the drug test" and "safe to operate" can be fatal. ClearGazeTest serves every sector where impaired function is a public safety crisis.
FAA regulations prohibit flying while impaired by any substance — including legally prescribed medications, cannabis, and alcohol within 8 hours of flight. But pre-flight impairment detection relies almost entirely on self-disclosure and peer reporting. The 2023 FAA mental health disclosure crisis revealed how deeply these systems fail. ClearGazeTest's 5-minute pre-flight screen provides the objective safety layer the system currently lacks.
One impaired pilot: up to 400 lives at risk per flight
FMCSA mandates drug and alcohol testing — but the testing program misses real-time impairment from fatigue, cannabis consumed on days off, and prescription medication side effects. Truck driver fatigue is implicated in 13% of all large truck crashes — and fatigue produces the same oculomotor biomarker signatures as cannabis and sedative drug impairment. ClearGazeTest catches both.
503,000 large truck crashes/year · 5,800+ fatalities (FMCSA)
FRA regulations require testing for alcohol and specific drug metabolites — but trains stop poorly and derailments kill. Post-incident testing consistently reveals impairment that pre-duty testing missed, because pre-duty testing measures past exposure, not present function. High-profile derailments have repeatedly involved employees who passed pre-employment drug tests.
Derailment at 60 mph: no second chance to test again
Mining, construction, port operations, and energy production all involve heavy equipment capable of killing operators and bystanders instantly. OSHA's post-incident drug testing rules create enormous liability tension — employers want to test after accidents, but doing so after a preventable impairment incident is too late. Pre-access ClearGazeTest shifts testing to where it matters: before.
Mining construction: highest occupational fatality rates in industry
Bus operators, subway motormen, and ferry pilots carry public passengers under FTA-mandated drug and alcohol programs. Fatigue among public transit operators is epidemic — and sleep-deprived operators produce oculomotor biomarker patterns indistinguishable from mild cannabis impairment. ClearGazeTest detects both, giving transit authorities the pre-shift safety tool they actually need.
Public transit incidents affect hundreds of passengers at once
Nuclear plant operators, chemical facility workers, and utility infrastructure personnel operate in environments where a single impaired decision can cause mass casualties or infrastructure failure. These industries already have the most stringent "fitness for duty" requirements of any sector — and ClearGazeTest provides the objective neurological assessment that the fitness-for-duty standard demands.
Nuclear fitness-for-duty: highest regulatory standard in any industry
Oculomotor biomarkers are involuntary neurological responses — they cannot be controlled, coached, or masked. Whatever substance or condition is affecting the brain right now will show in eye movement data within minutes.
Standard workplace drug testing programs leave critical safety gaps. Here's where each method succeeds — and where they fail.
| Scenario | Standard Drug Test | ClearGazeTest |
|---|---|---|
| Pilot impaired by Ambien taken 7hrs agoPrescription medication · Within metabolic window | ❌ Passes | ✓ Detected |
| Trucker who used cannabis 3 days ago, fully sober nowLegal state · No current impairment | ❌ Fails (false positive) | ✓ Clears as fit |
| Rail operator with 22 hours without sleepFatigue impairment · No substances involved | ❌ Passes | ✓ Detected |
| Equipment operator acutely impaired by cannabis used 2hrs agoRecent use · Active impairment | ⚠ May detect | ✓ Detected |
| Pilot taking prescribed opioid for legitimate pain, impairedValid Rx · Active impairment | ❌ Passes (legal Rx) | ✓ Detected |
| Employee using polydrug combination (alcohol + cannabis + fatigue)Common real-world scenario | ⚠ Partial (alcohol only) | ✓ Full combination detected |
Federal regulations establish minimum drug testing standards — but they were written before objective real-time impairment assessment existed. ClearGazeTest operates above the regulatory floor, not instead of it.
As states legalize cannabis, some have enacted employee protections limiting employer action based solely on a positive drug test for off-duty cannabis use. Employers whose policies are impairment-based rather than exposure-based are better positioned legally and operationally — and ClearGazeTest's objective impairment assessment provides exactly the kind of real-time, functional evidence that impairment-based policies require. Consult employment counsel for your specific state's requirements.
ClearGazeTest fits into existing safety workflows as a pre-access gate, a pre-departure check, or a return-to-duty evaluation. Here's how a standard program is structured.
Each safety-sensitive employee undergoes a baseline ClearGazeTest assessment when enrolling in the program — when known to be rested, sober, and unimpaired. This creates a personalized neurological profile for comparison, making subsequent assessments far more sensitive to individual deviations than population-norm comparisons alone.
✓ One-time enrollment · Refreshed annuallyBefore each shift, flight, or access to safety-sensitive areas, the employee completes the 5-minute ClearGazeTest protocol. The platform compares current biomarker values to their individual baseline and population norms. A pass/flag decision is generated instantly, along with a full biomarker report for the program administrator.
✓ 5 minutes · No disruption to shift schedulesA flagged assessment triggers your organization's pre-defined response protocol — typically a secondary clinical evaluation, supervisor interview, and if warranted, a drug/alcohol test for causal attribution. The employee is removed from safety-sensitive duty pending evaluation. The ClearGazeTest report is retained as part of the incident record. Critically, the assessment identifies impairment without naming a cause — protecting employer and employee until causal testing is completed.
✓ Pairs with existing DOT/OSHA response workflowsAfter medical treatment, substance use program completion, or resolved health condition, return-to-duty requires more than paperwork. ClearGazeTest provides documented, objective neurological clearance — serial assessments demonstrating that biomarker values have returned to individual baseline. Safety officers have quantified evidence supporting their return-to-duty decision, not a physician's note alone.
✓ Complements SAP evaluation process under DOT programsSafety is the core reason. But objective impairment assessment also transforms employer liability, insurance costs, and regulatory standing.
No — and it's not designed to. DOT drug testing programs are federal regulatory requirements for covered employers. ClearGazeTest is an objective impairment assessment tool that operates alongside your existing program. A flagged ClearGazeTest assessment may trigger a confirmatory drug/alcohol test; a passed drug test does not remove the need for impairment assessment before duty begins. The two tools measure different things and work best together.
Refusal to submit to an employer-required fitness-for-duty assessment is typically treated under the same policy framework as refusal to submit to drug testing — a policy violation that may result in removal from safety-sensitive duty pending review. Employers should have clear written policies establishing ClearGazeTest as a condition of access to safety-sensitive roles, reviewed by employment counsel and consistent with applicable state law. Contact us to discuss policy framework development.
No. Oculomotor biomarkers are involuntary physiological responses that cannot be consciously controlled. Saccadic velocity, pupillary constriction dynamics, and smooth pursuit gain are all governed by neurological processes below the level of voluntary control. An impaired person cannot suppress their increased saccadic latency or normalize their reduced smooth pursuit gain any more than they can voluntarily control their blood pressure. This is precisely why eye-based assessment is superior to questionnaire-based or observation-based methods.
The baseline enrollment process identifies pre-existing oculomotor conditions and creates an individualized baseline that accounts for them. Conditions that fundamentally alter specific biomarkers are flagged in the system, and those biomarkers are contextualized appropriately in subsequent assessments. The multi-biomarker approach provides redundancy — impairment from substances or fatigue produces a distinctive pattern across multiple biomarkers, not just the one that might be affected by a medical condition. Final interpretation is always in the hands of a qualified clinician.
The 2023 FAA mental health disclosure controversy revealed the degree to which aviation safety relies on voluntary self-disclosure — a system that demonstrably fails. ClearGazeTest does not replace mental health screening, which requires different clinical tools. However, many neuropsychiatric conditions that affect flight safety also produce measurable oculomotor biomarker changes — including depression treated with certain SSRIs, anxiety disorders, and fatigue-related decline. A pre-flight objective neurological assessment adds an independent functional safety layer that does not depend on pilot self-disclosure.
Implementation follows a phased approach: (1) baseline enrollment of all safety-sensitive employees, (2) integration of the 5-minute protocol into existing pre-shift/pre-flight workflows, (3) establishment of flag response protocols consistent with existing DOT/safety procedures, and (4) administrator training for safety officers. Contact us through the form below — a NeuroClear partner representative will reach out to discuss your fleet size, operational context, regulatory framework, and timeline.
For safety officers, HR directors, fleet managers, and occupational health directors across aviation, trucking, rail, and heavy industry — let's talk.